Rationally designed Inhibitors of the Plasmodium Proteasome β2-subunit as combination therapies for the treatment of ART-resistant Malaria (RIP-Malaria)

Rahman, Miraz (Primary Investigator)
Najer, Adrian (Co-Investigator)

Institute of Pharmaceutical Science

Project: Research

Acronym	RIP Malaria
Status	Active
Effective start/end date	1/10/2024 → 30/09/2025

Funding

UCL University College London: £64,115.10